Severe sepsis in autologous stem cell transplant recipients: Microbiological aetiology, risk factors and outcome

被引:29
作者
Hamalainen, Sari [1 ]
Kuittinen, T. [1 ]
Matinlauri, I. [2 ]
Nousiainen, T. [1 ]
Koivula, I. [1 ]
Jantunen, E. [1 ]
机构
[1] Kuopio Univ Hosp, Dept Med, FI-70211 Kuopio, Finland
[2] Kuopio Univ Hosp, Dept Clin Chem, FI-70211 Kuopio, Finland
关键词
ANTIBIOTIC-PROPHYLAXIS; NEUTROPENIC PATIENTS; FEBRILE NEUTROPENIA; CHEMOTHERAPY; INFECTIONS; FEVER;
D O I
10.1080/00365540802454706
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Infectious complications are the main reason for early treatment-related mortality after autologous stem cell transplantation (ASCT). We evaluated retrospectively microbiological aetiology, risk factors and clinical consequences of severe sepsis in this patient cohort. From 1996 to 2006 a total of 319 patients underwent ASCT at our institution. Antibacterial prophylaxis was not used. Neutropenic fever occurred in 83% (n = 265) and was complicated by severe sepsis in 5% (n = 17) of patients. Severe sepsis tended to be more common in patients with non-Hodgkin's lymphoma (NHL) than in other patients (9% vs 3%, p = 0.009). Bacteraemia was observed more commonly in patients with severe sepsis (76% vs 22%, p<0.001); Pseudomonas sp. was found in 30% (n = 5) of these patients. Kinetics of C-reactive protein (CRP) more commonly coincided with, rather than predicted, the development of severe sepsis. All other observed risk factors for severe sepsis (length of neutropenia, fever and blood culture findings) were late indicators. Severe sepsis was fatal in 9 patients (53%), and all had NHL (p = 0.003 compared to other patients). Severe sepsis is an important cause of early mortality after ASCT, especially in NHL patients. Ways to prevent development of severe sepsis or predict its development might reduce early mortality among ASCT recipients.
引用
收藏
页码:14 / 20
页数:7
相关论文
共 25 条
  • [1] [Anonymous], 2000, MMWR Recomm Rep, V49, P1
  • [2] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [3] Cherif Honar, 2003, Hematol J, V4, P420, DOI 10.1038/sj.thj.6200334
  • [4] Epidemiology and risk factors for gram-positive coccal infections in neutropenia: Toward a more targeted antibiotic strategy
    Cordonnier, C
    Buzyn, A
    Leverger, G
    Herbrecht, R
    Hunault, M
    Leclercq, R
    Bastuji-Garin, S
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) : 149 - 158
  • [5] Cordonnier C, 2005, HAEMATOLOGICA, V90, P1102
  • [6] The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit
    Craig, M.
    Cumpston, A. D.
    Hobbs, G. R.
    DeVetten, M. P.
    Sarwari, A. R.
    Ericson, S. G.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 (08) : 477 - 482
  • [7] Risk of neutropenic fever and early infectious complications after autologous peripheral blood stem cell transplantation for malignant diseases
    Fujii, K
    Aoyama, M
    Shinagawa, K
    Matsuo, K
    Takenaka, K
    Ikeda, K
    Kojima, K
    Ishimaru, F
    Kiura, K
    Ueoka, H
    Niiya, K
    Tanimoto, M
    Harada, M
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (02) : 186 - 191
  • [8] The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products
    Gratwohl, A.
    Baldomero, H.
    Frauendorfer, K.
    Rocha, V.
    Apperley, J.
    Niederwieser, D.
    [J]. BONE MARROW TRANSPLANTATION, 2008, 41 (08) : 687 - 705
  • [10] Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy:: Causes and consequences
    Hamalainen, Sari
    Kuittinen, Taru
    Marinlauri, Irma
    Nousiainen, Tapio
    Koivula, Irma
    Jantunen, Esa
    [J]. LEUKEMIA & LYMPHOMA, 2008, 49 (03) : 495 - 501